View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

Tricida updates timeline for CKD drug trial data amid Ukraine crisis

Top-line data from the VALOR-CKD trial of veverimer is now expected in the fourth quarter of this year.

Understand the impact of the Ukraine conflict from a cross-sector perspective with the Global Data Executive Briefing: Ukraine Conflict

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Tricida has updated the expected date for reporting top-line results from the VALOR-CKD clinical trial of investigational drug candidate, veverimer, for chronic kidney disease (CKD) amid Ukraine crisis.

Nearly 15% of the subjects randomised in the trial are from Ukraine, the company noted.

The trial is analysing whether veverimer has the ability to decelerate the progression of chronic CKD in metabolic acidosis linked to the disease. 

Veverimer is a non-absorbed, oral polymer intended to reduce CKD progression.

With the latest development, top-line trial results are now expected early in the fourth quarter of this year.

As of 1 March, the trial had 197 subjects with positively adjudicated primary endpoint events following an average treatment period of nearly 23 months.

End-stage renal disease, or greater than or equal to a 40% reduction in estimated glomerular filtration rate and renal death were the primary endpoint events of the trial.

In a press statement, Tricida said: “Given the uncertainty around future participation of Ukrainian subjects in the trial and the potential challenges to collecting and monitoring data from Ukrainian sites, top-line data from the VALOR-CKD trial is now anticipated early in the fourth quarter of 2022, versus Tricida’s previous guidance of the third quarter of 2022.

The guidance for reporting trial data was revised by the company on analysing the present situation in the country.

Tricida expects that additional time is required to deal with predicted interruptions and/or delays in collecting data. 

Furthermore, the company does not anticipate any impact on the usability of the results obtained from subjects in Ukraine.

The company believes that its financial resources will be sufficient for nearly six months after the expected reporting of top-line data from the study.

Tricida CEO and president Gerrit Klaerner said: “We are deeply concerned for the people of Ukraine, including the VALOR-CKD patients, investigators, site staff and our CRO colleagues who we have worked with for many years.

“We believe that an incremental delay of the administrative stop is prudent to obtain interpretable data from the VALOR-CKD trial with approximately the same number of events and six-months cash runway as outlined in our prior communications.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena